Quantcast

Latest Chiron Corporation Stories

2014-03-28 08:26:48

SAN DIEGO, March 28, 2014 /PRNewswire/ -- aTyr Pharma ("aTyr"), a rare disease biotherapeutics enterprise, announced today the appointment of Ed Penhoet, Ph.D., to the Company's board of directors (BOD). Dr. Penhoet, who co-founded Chiron, is an accomplished scientist and biotech pioneer. He has served on the Independent Citizens Oversight Committee (ICOC) for the California Institute of Regenerative Medicine (CIRM) and was recently appointed to President Obama's Council of...

2010-10-07 06:00:00

EAST HANOVER, N.J., Oct. 7 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced the availability of patient support programs for Gilenya(TM) (fingolimod) 0.5 mg daily, a first-line oral treatment for relapsing forms of multiple sclerosis. Gilenya was approved by the US Food and Drug Administration (FDA) on September 21, 2010. For people with MS and healthcare professionals seeking information about Gilenya, Novartis offers free programs to learn about educational...

2010-09-30 11:31:00

VIENNA, Sept. 30 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that effective October 1, 2010, Staph Leavenworth Bakali will join its Management Board as Chief Business Officer with key responsibilities for the commercial aspects of the Company, directly leading Marketing and Sales, Corporate and Business Development, and Alliance Management. Staph will also play a key role with the other Management Board members in helping drive forward the Company's strategy. Prior to the...

2009-01-27 15:00:00

- Companies Will Work Together to Protect World's Supply of Donated Blood from Infectious Diseases Until 2025 - Partners Anticipate Continued Expansion into New Global Markets and Development of Innovative New Products, Including Next-Generation PANTHER Instrument - Companies Also Plan Exploratory Collaboration in Pharmacogenomics - Gen-Probe Provides Preliminary 2009 Financial Guidance Including Additional Revenue and Profit from Agreement SAN DIEGO, Jan. 27 /PRNewswire-FirstCall/ --...

c1f829196fa8b3e80a991c519e374b311
2008-08-06 14:00:00

Six versions of the influenza vaccine were approved on Tuesday for the 2008-2009 flu season, U.S. health regulators said. The U.S. Food and Drug Administration announced the approval of various vaccines by GlaxoSmithKline Plc's Fluarix and FluLaval; Novartis AG's Fluvirin; Sanofi Aventis SA's Fluzone and CSL Ltd's Afluria. The FluMist nasal spray flu vaccine made by AstraZeneca Plc unit MedImmune was also given approval, according to the FDA. The same three strains of the influenza virus are...

2008-07-24 12:01:22

Dynavax Technologies has signed an agreement with Novartis Vaccines and Diagnostics for the supply and development, and possible commercialization, of Dynavax's novel universal influenza vaccine in collaboration with Novartis. Under the agreement Novartis will provide Dynavax a supply of trivalent influenza vaccine, an essential component of Dynavax's Universal Influenza Vaccine, for both clinical trial use and vaccine sales. Novartis receives an exclusive option to negotiate a joint...

2008-07-23 09:01:21

Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has added Mustapha Leavenworth Bakali to its Board of Directors as Executive Director. "Staph has been instrumental in building some of the most successful vaccine companies in the world," said Genocea Chief Executive Officer Robert Paull. "His diverse operational, deal-making, and entrepreneurial experience in vaccines is the perfect complement to the leading scientific minds we've attracted...

2006-03-16 09:50:00

CHICAGO (Reuters) - Chiron Corp. on Thursday said it is recalling and withdrawing its measles, mumps and rubella vaccine, MORUPAR, from Italian and developing world markets because it may be associated with a higher rate of adverse side effects than other such vaccines. The adverse events on which the recall and withdrawal are based are within a range of those commonly associated with vaccines, such as fever, allergic reactions and swelling of the glands, Chiron said. As a result of the...

997d2dffcc27caa1a4a0413903b75ac51
2005-12-04 11:35:00

SAN FRANCISCO -- Two years ago, as fears of a SARS pandemic spread, a San Diego biotech company aided by federal dollars speeded a promising vaccine out of the lab and into human testing. But when Vical Inc. (VICL) and the government wrap up the 15-person test next year, the drug is expected to end up on the shelf because the dreaded global epidemic never panned out. Bird flu has now overtaken SARS as the No. 1 feared global death threat. As biotechnology companies suddenly refocus their...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related